

ASTRAZENECA PLC
Form 6-K
May 03, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of May 2016

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____

ASTRAZENECA COMPLETES DIVESTMENT OF IMDUR
TO CHINA MEDICAL SYSTEM HOLDINGS

Edgar Filing: ASTRAZENECA PLC - Form 6-K

AstraZeneca today announced that it has completed the divestment of the global rights to Imdur, outside the US, to China Medical System Holdings Ltd and its associated company, Tibet Rhodiola Pharmaceutical Holding Co. Under the agreement, AstraZeneca will receive \$190 million for the rights to Imdur.

Imdur is a mature medicine for the prevention of angina in patients with heart disease and achieved global sales outside the US of \$57 million in 2015. Income from the agreement will be reported as Core Other Operating Income.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries

| | | |
|------------------|-----------|------------------|
| Neil Burrows | UK/Global | +44 20 7604 8032 |
| Vanessa Rhodes | UK/Global | +44 20 7604 8037 |
| Karen Birmingham | UK/Global | +44 20 7604 8120 |
| Jacob Lund | Sweden | +46 8 553 260 20 |
| Michele Meixell | US | +1 302 885 2677 |

Investor Enquiries

UK

| | | |
|---------------------|---------------------|-----------------|
| Thomas Kudsk Larsen | | +44 7818 524185 |
| Eugenia Litz | RIA | +44 7884 735627 |
| Nick Stone | CVMD | +44 7717 618834 |
| Craig Marks | Finance | +44 7881 615764 |
| Christer Gruvris | Consensus Forecasts | +44 7827 836825 |

US

| | | |
|------------------|---------------|-----------------|
| Lindsey Trickett | Oncology, ING | +1 240 543 7970 |
| Mitch Chan | Oncology | +1 240 477 3771 |
| Dial / Toll-Free | | +1 866 381 7277 |

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience and Gastrointestinal

03 May 2016

-ENDS-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 03 May 2016

By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary